




Diagnostics

Biomarkers for Amyotrophic Lateral Sclerosis (ALS)

A research group from the Andalusian Public Health System (SSPA) has developed a kit for the diagnosis, prognosis and / or monitoring of Amyotrophic Lateral Sclerosis (ALS).

Oficina de
**TRANSFERENCIA
DE TECNOLOGÍA**
Sistema Sanitario Público de Andalucía



Description

Nowadays, there are not cure or good treatments for ALS, but early detection or diagnosis and management of the disease, could lead to improve the quality of life for patients.

In ALS can occur long delays between the onset of symptoms and the establishment of a formal diagnosis since in the early stages can be difficult to discern the ALS from other motor neuron diseases. Therefore, there is a critical need to identify low cost and reliable noninvasive biomarkers.

In this context, a research group from the Andalusian Public Health System (SSPA) has developed a kit for the diagnosis, prognosis and / or monitoring of amyotrophic lateral sclerosis. The research group has found that two markers are overexpressed in peripheral blood mononuclear cells (PBMCs) of patients with ALS disease.



Advantages

1. Early diagnosis of ALS patients.
2. A non invasive technique.
3. Optimization of treatments in ALS patients.



Intellectual Property

The technology is protected by a patent application.



Aims

The research group is looking for a collaboration agreement for further development or a licence agreement.



Classification

Area: Diagnostic

Pathology: Central Nervous System / Musculoskeletal disorders